Weight-loss drug developers line up to tap market worth $150 billion

Wegovy by Novo Nordisk and Zepbound by Eli Lilly currently dominate the weight-loss drug market and are expected to remain the top choices in a market projected to reach a value of 150 billion by the early 2030s.

novo-nordisk

However, numerous other pharmaceutical companies are looking to capitalize on the trend well. Below are the names of publicly traded companies that are focused on pursuing the next major breakthrough in the industry:

 

NOVO NORDISK

In a recent study, amycretin, the newest drug from Novo, resulted in a weight loss of 13.1% among obese individuals following a 12-week treatment period. This outcome stands in contrast to the 6% weight loss observed in a trial for Wegovy over the same duration.

Novo has announced its intention to initiate a Phase II clinical trial for amycretin in the latter part of this year, with the expectation of receiving findings by the beginning of 2026.

In August, Novo Nordisk released findings from a major clinical trial, revealing that Wegovy also demonstrated a significant advantage in reducing cardiovascular risks. Notably, Wegovy shares the same active compound as Novo’s diabetes medication Ozempic, and received approval in 2021.

In June, the pharmaceutical company released results from advanced testing of a strong oral form of its medication, semaglutide. The data showed that overweight or individuals were able to achieve a weight loss of 15 which was consistent with findings from new obesity medications.

In a deal valued at $11 billion, the company announced in February that it will acquire three manufacturing facilities from Novo Holdings, once Novo’s purchase of Catalent is finalized. The sites, located in Anagni, Italy, Brussels, Belgium, and Bloomington, Indiana, will enhance the company’s capacity to produce Wegovy, a key product in its portfolio.

 

ELI LILLY

Eli Lilly’s new weight-loss treatment, Zepbound, was approved by regulators in the United States and the United in November. This approval the stage for a strong competitor to Novo’s Wegovy.

In December, the company disclosed that Zepbound generated sales of $175.8 million in its initial weeks on the market. This medication, also called tirzepatide, was previously marketed as Mounjaro for managing type 2 diabetes starting in 2022 and was commonly used for weight loss purposes despite not being officially approved for that use.

In June, Lilly reported that a mid-stage study of its new obesity medication, retatrutide, which is given as a weekly injection, resulted in weight loss of as much as 24.2% over a period of 48 weeks.

 

PFIZER

In a December announcement, Pfizer revealed it would be halting additional testing of a twice-daily formulation of its oral medication, danuglipron, intended to aid in weight reduction.

Following a mid-stage trial marked by a high patient dropout rate due to severe nausea and vomiting, the decision has been made to reassess the treatment’s viability.

The organization has shifted its attention to a new, sustained-release formulation of danuglipron, designed to be taken just once a day. Results detailing how this revised formula behaves within the body are anticipated to be revealed in the coming year.

In June, Pfizer decided to halt the progress of its daily pill because of worries about potential liver risks.

ROCHE AND CARMOT THERAPEUTICS

As a result of its $2.7 billion acquisition of Carmot Therapeutics, Roche gained control of CT-388. This weekly injectable medication falls under the same category as Mounjaro, also known as Zepbound, which is produced by Eli Lilly. 

Roche announced that the recently obtained experimental drug has successfully finished initial testing and is prepared for further evaluation on human participants in the second phase of clinical trials.

 

AMGEN

During a 12-week clinical trial, Amgen’s innovative obesity medication, AMG133, achieved an average weight reduction of 14.5% among participants receiving the maximum monthly dosage, as revealed in November.

 

ALTIMMUNE

In November, Altimmune announced that their drug pemvidutide demonstrated an average weight reduction of 15.6% and sustained weight loss at the completion of a mid-stage trial.

Additionally, some individuals reported mild to moderate cases of stomach upset, including queasiness and vomiting.

 

VIKING THERAPEUTICS

In February, Viking Therapeutics announced that their new medication, VK2735, resulted in notable weight loss for obese patients during a mid-phase trial.

Data from the study showed that VK2735 assisted 176 overweight adults with at least one weight-related comorbidity in average weight loss of up to 14.7% after 13 weeks of treatment.

Share:

More Posts

chemical-hair-relaxer-lawsuit

How Much Money Can I Get From The Hair Relaxer Lawsuit?

Chemical hair relaxers are extensively used throughout these products in the United States. Still, evidence is pointing to a link between the utilization of these items and the development of uterine cancer. This has resulted in numerous hair relaxer lawsuit against the manufacturers and distributors of these products.

johnson_&_johnson

J&J acquires experimental skin disorder drug for $1.25 billion

Johnson & Johnson, opening new tabs on Tuesday, has agreed to purchase exclusive rights for an innovative treatment for skin disorders from privately owned Numab Therapeutics for about $1.25 billion. This is the second acquisition with an eczema-focused business this month.

Send Us A Message

Discover our range of legal services covering product liability, mass tort, and personal injury cases. Let us guide you through legal challenges to achieve justice.

Contact Us

Email Us : info@claimantlegalhelp.com
We are open from Monday to Friday
09.00 AM - 17.00 PM
Sheridan WY 82801

Our Legal Services

Quick Links

Copyright 2023 © All Right Reserved Claimantlegalhelp.com